@article {1494,
	title = {First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial.},
	journal = {AIDS (London, England)},
	volume = {25},
	year = {2011},
	month = {2011 Feb 20},
	pages = {479-92},
	abstract = {The OCTANE trial reports superior outcomes of lopinavir/ritonavir vs. nevirapine-based antiretroviral therapy (ART) among women previously exposed to single-dose nevirapine to prevent mother-to-child HIV transmission. However, lopinavir/ritonavir is 12 times costlier than nevirapine.},
	keywords = {Adult, Anti-HIV Agents, Cost-Benefit Analysis, Female, HIV Infections, Humans, Infant, Newborn, Infectious Disease Transmission, Vertical, Life Expectancy, Lopinavir, Male, Nevirapine, Pregnancy, Pyrimidinones, Ritonavir, South Africa, Treatment Outcome},
	issn = {1473-5571},
	doi = {10.1111/j.1524-4733.2010.00763.x},
	author = {Ciaranello, Andrea L and Lockman, Shahin and Freedberg, Kenneth A and Hughes, Michael and Chu, Jennifer and Currier, Judith and Wood, Robin and Holmes, Charles B and Pillay, Sandy and Conradie, Francesca and McIntyre, James and Losina, Elena and Walensky, Rochelle P}
}
